IL-28β gene polymorphism determines virological response to PEGylated interferon therapy in hepatitis C virus genotype 4 Egyptian patients.

Nashwa El-KhazragyNaglaa El SayedAhmed M SalemNahla S HassanAmal Tohamy AbdelmoeazAmany M MaherAzza El-Sayed Mansy

Published in: Journal of cellular biochemistry (2018)

we conclude that IL28B polymorphism is highly associated with SVR to therapy in the Egyptian population infected with HCV genotype 4 and patients who carry CC genotype have a higher chance of SVR.

Keyphrases

hepatitis c virus
end stage renal disease
human immunodeficiency virus
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
hiv infected
stem cells
dendritic cells
patient reported outcomes
immune response
bone marrow
cell therapy
patient reported
replacement therapy